Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean
21 November 2019 - 4:11PM
InvestorsHub NewsWire
Full Alliance Group Announces New
EBO2 Sites in Florida and the Caribbean
BEVERLY HILLS, CA -- November 21, 2019 -- InvestorsHub NewsWire
-- Full Alliance Group, Inc. (OTCPK:FAGI)
is pleased to announce the opening of two new EBO2 treatment
offices.
Dr. Yu and his staff arrived in Boca Raton, Florida, and then the
Cayman Islands earlier this week with two brand-new portable EBO2
units and are currently training Dr. Joseph Purita and his
staff. Dr. Purita is well-known in the stem cell and
regenerative medicine sector and is eager to implement our ozone
technology within his thriving practice. He has offices in
Boca Raton as well as in the Cayman Islands.
Dr. Purita’s Pensum Regenerative Clinic in Grand Cayman already
specializes in stem cell treatment and anti-aging. The
addition of EBO2 technology is expected to work synergistically
with the well-established stem cell protocols already in place at
the clinic.
“Expanding our footprint to the East and South, as well as the
Caribbean, has been a critical part of our strategic plan,” said
Dr. Brian Volpp, MD, CEO and President of Full Alliance Group, Inc.
“We are grateful that Dr. Purita has committed to the Yu Method and
that he has made the financial commitment for two of our new
units. His reputation within the stem cell community should
allow ozone therapy to become more mainstream as he gains more
experience with integrating EBO2 into his existing protocols.”
Also, we have been advised by our legal team that the third quarter
financial filing must be made publicly available to all
shareholders. Consequently, the filing has been posted on our
website: https://FullAlliance.com
Sincerely,
Paul Brian Volpp, MD, MPH,
President / CEO
The Full Alliance Group
About Full Alliance Group Inc.
Full Alliance Group Inc. (OTCPK:
FAGI) is a multi-faceted holding company with various interests
in technology, healthcare, and nutraceuticals. Nutra Yu, Inc., a
wholly owned subsidiary of Full Alliance Group, develops, markets,
and distributes a proprietary line of nutraceutical products.
EBO2, Inc., a wholly owned subsidiary of Full Alliance Group, is
the provider of ''EBO2'', a modern high volume blood gas exchange
unit for the treatment of 5-7 liters of blood with medical ozone.
The unit allows extracorporeal blood and oxygenation, ozone
exposure and blood filtration. The process filters blood in a
unique way by using the integrated diffusing membranes within the
filter fibers to trap lipids and proteins which are in excess in
the venous blood supply. The EBO2 unit is considered the world's
most advanced medical ozone therapy.
For additional information regarding Full Alliance Group, visit,
www.fullalliance.com.
Full Alliance Group Inc. Investor Relations
Dave Donlin
Email: Info@TheCervelleGroup.com
Phone: (407) 490-6635
Web: www.StockInvestorDaily.com
Visit: www.fullalliance.com
Contact: ir@fullalliance.com
Forward-Looking Statements
This shareholder update may contain a number of forward-looking
statements. Words and variations of words such as: “expect”,
“goals”, “could”, “plans”, “believe”, “continue”, “may”, “will”,
and similar expressions are intended to identify our
forward-looking statements, including but not limited to: our
expectation for growth, benefits from brand-building, cost savings
and margins. These forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond our
control, which could cause our actual results to differ materially
from those indicated in our forward-looking statements. Such
factors include, but are not limited to: continued volatility of,
and sharp increase in: costs/pricing actions, increased
competition, ability to raise sufficient operating capital, risks
from operating internationally, consumer weakness, weakness in
economic conditions and tax law changes.
Full Alliance (PK) (USOTC:FAGI)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Full Alliance (PK) (USOTC:FAGI)
Historical Stock Chart
Von Nov 2023 bis Nov 2024